Table I.
Patient demographic characteristics at baseline.
| Characteristic | AS group (n=49) | GS group (n=52) |
|---|---|---|
| Age, years | ||
| Median (IQR) | 63 (36–75) | 62 (39–73) |
| <65, n (%) | 30 (61.22) | 36 (69.23) |
| ≥65, n (%) | 19 (38.78) | 16 (30.77) |
| Sex, n (%) | ||
| Male | 30 (61.22) | 39 (75.00) |
| Female | 19 (38.78) | 13 (25.00) |
| ECOG PS, n (%) | ||
| 0 | 1 (2.04) | 1 (1.92) |
| 1 | 48 (97.96) | 51(98.08) |
| CA199a, U/ml, median (range) | 345.00 (2.00–10,000.00) | 276.00 (2.00–10,000.00) |
| CA125b, U/ml, median (range) | 35.50 (7.20–3,505.00) | 37.45 (9.00–852.00) |
| Location, n (%) | ||
| Pancreatic head | 26 (53.06) | 22 (42.31) |
| Pancreatic body | 6 (12.24) | 12 (23.08) |
| Pancreatic tail | 8 (16.33) | 9 (17.31) |
| Accumulated multiple sites | 9 (18.37) | 9 (17.31) |
| Stages, n (%) | ||
| III | 17 (34.69) | 20 (38.46) |
| IV | 32 (65.31) | 32 (61.54) |
| Metastasis sites, n (%) | ||
| 0 | 17 (34.69) | 20 (38.46) |
| 1 | 20 (40.81) | 22 (42.31) |
| 2 | 7 (14.29) | 7 (13.46) |
| 3 | 4 (8.16) | 2 (3.85) |
| 4 | 1 (2.04) | 1 (1.92) |
a
Normal range, 0–40 U/ml;
b
normal range, 0–35 U/ml. ECOG PS scores: 0, normal activity; 1, symptoms but the patient is nearly fully ambulatory. Stages: III, regional lymph node metastasis without distant metastasis; IV, distant metastasis. AS, nab-paclitaxel plus S-1; GS, gemcitabine plus nab-paclitaxel; IQR, interquartile range; ECOG PS, Eastern Cooperative Oncology Group performance status.